He discusses the profile of the therapy both as monotherapy and in combination, and compares and contrasts it to competitor data. Plus, the success factors behind Avidity Biosciences, which he co-founded and was recently acquired by Novartis for $12 billion. Coverage brought to you by

He describes the data Kura has presented at ASH and where he believes it puts the company in the competive picture, including why 1L is...

Troy Wilson describes the science behind Kura's menin inhibitor and farnesyl transferase inhibitor programs.